Liver failure in total artificial heart therapy

The total artificial heart in a cardiac replacement therapy programme.

Total Artificial Heart

Table of

Total Artificial Heart

Table of

Multi-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients.

To prevent thrombotic or bleeding events in patients receiving a total artificial heart (TAH), agents have been used to avoid adverse events. The purpose of this article is to outline the adoption and results of a multi-targeted antithrombotic clinical procedure guideline (CPG) for TAH patients. Based on literature review of TAH anticoagulation and multiple case series, a CPG was designed to pr...

Total artificial heart freedom driver in a patient with end-stage biventricular heart failure.

Approximately 5.7 million people in the United States have a diagnosis of heart failure, and more than 3,100 patients are awaiting a heart transplant. A temporary total artificial heart (TAH-t, SynCardia Systems Inc, Tucson, Arizona) is approved by the US Food and Drug Administration (FDA) as a bridge to transplant in patients at risk of dying of biventricular heart failure. Currently, TAH-t re...